Table 2.
Comparison of clinical and biochemical variables between patients who developed and did not develop cancer during the follow-up period.
| No cancer (n = 591) | Cancer (n = 62) |
p-value | |
|---|---|---|---|
| Age (years) | 55.1 ± 15.8 | 54.9 ± 12.8 | ns |
| BMI (Kg/sqm) | 26.7 ± 6.4 | 26.4 ± 5.5 | ns |
| Waist Circumference (cm) | 94.7 ± 15.2 | 95.0 ± 13.4 | ns |
| FPG (mg/dL) | 96.4 ± 28.8 | 104.1 ± 47.5 | ns |
| AST (U/L) | 21.9 ± 8.2 | 36.8 ± 2.5 | < 0.001 |
| ALT (U/L) | 28.6 ± 16.0 | 29.0 ± 12.6 | ns |
| GGT (U/L) | 29.1 ± 30.0 | 28.4 ± 25.1 | ns |
| Total Cholesterol (mg/dL) | 189.5 ± 41.5 | 194.2 ± 39.2 | ns |
| HDL Cholesterol (mg/dL) | 59.1 ± 15.1 | 60.0 ± 17.7 | ns |
| LDL Cholesterol (mg/dL) | 108.2 ± 33.5 | 110.7 ± 34.1 | ns |
| Triglycerides (mg/dL) | 108.5 ± 63.9 | 113.0 ± 53.0 | ns |
| Platelet Count (× 103/L) | 251.7 ± 61.5 | 241.7 ± 85.7 | ns |
| AARPRI score | 0.5 ± 0.3 | 0.9 ± 0.6 | < 0.001 |
| APRI score | 0.3 ± 0.1 | 0.5 ± 0.3 | < 0.001 |
| FIB-4 score | 1.0 ± 0.6 | 1.8 ± 1.3 | < 0.001 |
| mFIB-4 score | 2.0 ± 1.3 | 3.4 ± 2.6 | < 0.001 |
Data is presented as mean ± SD (Standard Deviation). Comparisons were performed by Mann–Whitney U Test, and statistical significance was assessed for p-values < 0.05.
BMI, body mass index; FPG, fasting glucose plasma; AST, aspartate transferase; ALT, alanine transferase; GGT: gamma-glutamyl transpeptidase; ALP, alkaline phosphatase; AARPRI, (AST to ALT ratio) to platelet ratio index; APRI, AST-platelet ratio index; mAPRI, modified APRI; FIB-4, fibrosis-4 index; mFIB-4, modified FIB-4.